Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1991 1
1992 3
1993 2
1994 5
1995 7
1996 4
1997 2
1998 4
1999 2
2000 4
2001 2
2002 6
2003 5
2004 6
2005 2
2006 5
2007 5
2008 9
2009 10
2010 6
2011 11
2012 7
2013 8
2014 8
2015 5
2016 6
2017 7
2018 4
2019 8
2020 9
2021 6
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer. Aapro MS, et al. Among authors: pettengell r. Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20. Eur J Cancer. 2011. PMID: 21095116
Pegfilgrastim.
Willis F, Pettengell R. Willis F, et al. Among authors: pettengell r. Expert Opin Biol Ther. 2002 Dec;2(8):985-92. doi: 10.1517/14712598.2.8.985. Expert Opin Biol Ther. 2002. PMID: 12517276 Review.
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Zucca E, et al. Among authors: pettengell r. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29. J Clin Oncol. 2017. PMID: 28355112 Free article. Clinical Trial.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. Pfreundschuh M, et al. Among authors: pettengell r. Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21. Lancet Oncol. 2011. PMID: 21940214 Clinical Trial.
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. Pfreundschuh M, et al. Among authors: pettengell r. Lancet Oncol. 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7. Lancet Oncol. 2006. PMID: 16648042 Clinical Trial.
Addressing frailty in patients with breast cancer: A review of the literature.
Jauhari Y, Gannon MR, Dodwell D, Horgan K, Tsang C, Clements K, Medina J, Tang S, Pettengell R, Cromwell DA. Jauhari Y, et al. Among authors: pettengell r. Eur J Surg Oncol. 2020 Jan;46(1):24-32. doi: 10.1016/j.ejso.2019.08.011. Epub 2019 Aug 12. Eur J Surg Oncol. 2020. PMID: 31439357 Review.
The double life of HOXB4.
Morgan R, Pettengell R, Sohal J. Morgan R, et al. Among authors: pettengell r. FEBS Lett. 2004 Dec 3;578(1-2):1-4. doi: 10.1016/j.febslet.2004.11.002. FEBS Lett. 2004. PMID: 15581606 Free article. Review.
Pixantrone maleate for non-Hodgkin's lymphoma.
Mukherji D, Pettengell R. Mukherji D, et al. Among authors: pettengell r. Drugs Today (Barc). 2009 Nov;45(11):797-805. doi: 10.1358/dot.2009.45.11.1438459. Drugs Today (Barc). 2009. PMID: 20126672 Review.
Pixantrone: merging safety with efficacy.
Papadatos-Pastos D, Pettengell R. Papadatos-Pastos D, et al. Among authors: pettengell r. Expert Rev Hematol. 2013 Feb;6(1):25-33. doi: 10.1586/ehm.12.61. Expert Rev Hematol. 2013. PMID: 23373776 Review.
148 results